<DOC>
	<DOCNO>NCT02465593</DOCNO>
	<brief_summary>This phase Ib/II study prospective , open-label , single arm , nonrandomized study PEP503 ( radio-enhancer ) . There 2 portion study . - Escalation phase ( Part Ib ) : A 3 + 3 dose escalation study design adopt phase identify recommend injection volume PEP503 intratumor injection . - Expansion phase ( Part II ) : Following confirmation recommend volume intratumor injection , 18 additional patient enrol recommended volume level evaluate efficacy .</brief_summary>
	<brief_title>A Study PEP503 ( Radio-enhancer ) With Radiotherapy Chemotherapy Patients With Rectal Cancer</brief_title>
	<detailed_description>The target population compose patient confirm adenocarcinoma rectum T3-4 , N , locally unresectable , tumor distal margin within 10 cm anal verge , evidence distant metastatic disease , ECOG performance 0-1 , adequate bone marrow , renal hepatic function .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Inclusion Criteria Histologically proven adenocarcinoma rectum T34 , N , locally unresectable disease , without evidence distant metastasis ( M0 ) Distant border tumor must locate ≤ 10 cm anal verge Staging MRI , transrectal ultrasound CTscan confirm stage resectability ECOG performance 0 1 Age : 20 80 year old Adequate bone marrow , renal , hepatic function : absolute neutrophil count ( ANC ) ≥ 1,500/mm3 platelet count ≥ 100,000/mm3 total bilirubin ≤ 1.5x upper limit normal ( ULN ) aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5x ULN alkaline phosphatase ( ALP ) within normal range calculate creatinine clearance ≥ 50 mL/min All female patient childbearing potential must negative urine pregnancy test within 7 day prior study treatment PEP503 . Patients must agree use effective contraception study Prior history pelvic radiation therapy Hypersensitivity fluoropyrimidine Uncontrolled serious medical psychiatric illness Myocardial infarction uncontrolled angor pectoris ( angina ) within prior 6 month No 4 week since prior participation investigational drug study Major surgery within 28 day Other malignancy within past 3 year except effectively treat squamous cell basal cell skin cancer , melanoma situ , carcinoma situ cervix , carcinoma situ colon rectum Cardiovascular disease would preclude study treatment followup Informed consent duly sign dated participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>